Shares of Alpine Immune Sciences, Inc. (ALPN) are falling more than 11% Tuesday morning after the clinical-stage immunotherapy company priced its public offering of 8.8 million shares, and pre-funded warrants to purchase up to 3.2 million shares.
The shares are being offered at $12.50 per share and the pre-funded warrants at $12.499 per pre-funded warrant.
The gross proceeds from the offering, which is expected to close by November 9, are estimated to be about $150 million.
ALPN, currently at $12.54, has traded in the range of $5.36 - $16.26 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.